EUVIMEDEUVIMED entdecken
Editorial

Unintended Financial Barriers: When “Generic” Does Not Mean Affordable

Jill DiStefano, Natalie W Pierson

Journal of Cardiac Failure · 2026-07 · 32 (7) · 1285-1287

DOI: 10.1016/j.cardfail.2026.06.009 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Cardiac Failure, 2026-07. Verfasst von Jill DiStefano und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Aminobutyrates, Angiotensin Receptor Antagonists, Drugs, Generic, Heart Failure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sacubitril/valsartan is a foundational component of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), demonstrating reductions in cardiovascular mortality and hospitalization in PARADIGM-HF. The introduction of generic sacubitril/valsartan was expected to improve affordability and expand access. However, real-world experience suggests that financial and administrative barriers persist despite generic availability. High deductibles under Medicare Part D, variable formulary placement, loss of manufacturer copay assistance, prior authorization requirements, and digital enrollment barriers continue to disrupt therapy continuity. These obstacles disproportionately affect elderly and socioeconomically vulnerable patients and contribute to cost-related nonadherence, treatment interruption and 'financial toxicity': the negative effects of the economic burden of medical care on patients. From a frontline clinical perspective, financial toxicity functions as a modifiable risk factor in HFrEF management. Aligning benefit design with evidence-based care is necessary to ensure that generic availability translates into sustained access and clinical benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminobutyratesAngiotensin Receptor AntagonistsDrugs, GenericHeart FailureTetrazolesHumansBiphenyl CompoundsDrug CombinationsHealth Services AccessibilityMedicare Part DUnited StatesValsartan

Substanzen

AminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsDrugs, Genericsacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan

Zitieren

APA

DiStefano, J., & Pierson, N. W. (2026). Unintended Financial Barriers: When “Generic” Does Not Mean Affordable. Journal of Cardiac Failure, 32(7), 1285-1287. https://doi.org/10.1016/j.cardfail.2026.06.009

Vancouver

DiStefano J, Pierson NW. Unintended Financial Barriers: When “Generic” Does Not Mean Affordable. Journal of Cardiac Failure. 2026;32(7):1285-1287. doi:10.1016/j.cardfail.2026.06.009

BibTeX
@article{DiStefano2026,
  author = {DiStefano, Jill and Pierson, Natalie W},
  title = {Unintended Financial Barriers: When “Generic” Does Not Mean Affordable},
  journal = {Journal of Cardiac Failure},
  year = {2026},
  volume = {32},
  number = {7},
  pages = {1285--1287},
  doi = {10.1016/j.cardfail.2026.06.009}
}
Kostenlos starten →